Literature DB >> 17710485

Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization.

Katsunaka Mikami1, Masaru Suzuki2, Hiroshi Kitagawa1, Masaki Kawakami1, Nobuaki Hirota1, Hiromichi Yamaguchi1, Osamu Narumoto1, Yoshiko Kichikawa1, Makoto Kawai1, Hiroyuki Tashimo1, Hidenori Arai1, Tadashi Horiuchi1, Yoshio Sakamoto1.   

Abstract

BACKGROUND: Recent studies suggested that administration of corticosteroids may improve clinical outcomes in patients with severe pneumonia.
OBJECTIVES: The aim of this study was to assess the effectiveness of corticosteroids as an adjunctive therapy in community-acquired pneumonia (CAP) requiring hospitalization. DESIGN AND
SETTING: An open label, prospective, randomized control study was conducted from September 2003 to February 2004 in a community general hospital in Japan. PATIENTS: Thirty-one adult CAP patients who required hospitalization were enrolled. MEASUREMENTS AND
RESULTS: Fifteen patients received 40 mg of prednisolone intravenously for 3 days (steroid group). Sixteen patients did not receive prednisolone (control group). Both groups were also evaluated for their adrenal function. The primary endpoint was length of hospital stay. Secondary endpoints were duration of intravenous (IV) antibiotics and time required to stabilize vital signs. Both groups demonstrated similar baseline characteristics and length of hospital stay, and yet a shorter duration of IV antibiotics was observed in the steroid group (p < 0.05). In addition, vital signs were stabilized earlier in the steroid group (p < 0.05). These differences were more prominent in the moderate-severe subgroup but not as significant in the mild-moderate subgroup. The prevalence of relative adrenal insufficiency (RAI) in both groups was high (43%), yet there was no difference in baseline characteristics between patients, with or without RAI. In multiple regression models, RAI seemed to have no influence on clinical courses.
CONCLUSIONS: In moderate-severe CAP, administration of corticosteroids promotes resolution of clinical symptoms and reduces the duration of intravenous antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17710485     DOI: 10.1007/s00408-007-9020-3

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   3.777


  27 in total

1.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.

Authors:  M S Niederman; L A Mandell; A Anzueto; J B Bass; W A Broughton; G D Campbell; N Dean; T File; M J Fine; P A Gross; F Martinez; T J Marrie; J F Plouffe; J Ramirez; G A Sarosi; A Torres; R Wilson; V L Yu
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

Review 2.  Corticosteroid insufficiency in acutely ill patients.

Authors:  Mark S Cooper; Paul M Stewart
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

Review 3.  Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia.

Authors:  Thomas M File
Journal:  Clin Infect Dis       Date:  2004-09-01       Impact factor: 9.079

Review 4.  Macrophages and polymorphonuclear neutrophils in lung defense and injury.

Authors:  Y Sibille; H Y Reynolds
Journal:  Am Rev Respir Dis       Date:  1990-02

Review 5.  Multiple system organ failure. Is mechanical ventilation a contributing factor?

Authors:  A S Slutsky; L N Tremblay
Journal:  Am J Respir Crit Care Med       Date:  1998-06       Impact factor: 21.405

6.  Expression of pro-inflammatory cytokines by flow-sorted alveolar macrophages in severe pneumonia.

Authors:  U Maus; S Rosseau; U Knies; W Seeger; J Lohmeyer
Journal:  Eur Respir J       Date:  1998-03       Impact factor: 16.671

7.  Risk of infectious complications in patients taking glucocorticosteroids.

Authors:  A E Stuck; C E Minder; F J Frey
Journal:  Rev Infect Dis       Date:  1989 Nov-Dec

8.  Dexamethasone in adults with bacterial meningitis.

Authors:  Jan de Gans; Diederik van de Beek
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

9.  Quality of care, process, and outcomes in elderly patients with pneumonia.

Authors:  T P Meehan; M J Fine; H M Krumholz; J D Scinto; D H Galusha; J T Mockalis; G F Weber; M K Petrillo; P M Houck; J M Fine
Journal:  JAMA       Date:  1997-12-17       Impact factor: 56.272

10.  Patterns of cytokine expression in community-acquired pneumonia.

Authors:  A J Puren; C Feldman; N Savage; P J Becker; C Smith
Journal:  Chest       Date:  1995-05       Impact factor: 9.410

View more
  38 in total

1.  Severity of community-acquired pneumonia treated with low-dose adjunctive corticosteroid.

Authors:  Katsunaka Mikami; Masaru Suzuki; Hiroshi Kitagawa; Masaki Kawakami; Nobuaki Hirota; Ayako Shimbara-Mikami; Yoshio Sakamoto
Journal:  Crit Care       Date:  2011-11-08       Impact factor: 9.097

2.  Efficacy and safety of glucocorticoids in the treatment of community-acquired pneumonia: A meta-analysis of randomized controlled trials.

Authors:  Li-Ping Chen; Jun-Hui Chen; Ying Chen; Chao Wu; Xiao-Hong Yang
Journal:  World J Emerg Med       Date:  2015

3.  Evaluation of Systemic Corticosteroids in Patients With an Acute Exacerbation of COPD and a Diagnosis of Pneumonia.

Authors:  Tyler Scholl; Tyree H Kiser; Sheryl F Vondracek
Journal:  Chronic Obstr Pulm Dis       Date:  2018-01-24

4.  Corticosteroids for Community-Acquired Pneumonia: Overstated Benefits and Understated Risks.

Authors:  Grant Waterer; Mark L Metersky
Journal:  Chest       Date:  2019-07-06       Impact factor: 9.410

5.  Adjuvant corticosteroids for patients hospitalized with community-acquired pneumonia: is it time?

Authors:  Matthieu Revest; Gérald Egmann; Anthony Chapron; Stéphane Jouneau; Pierre Tattevin
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

6.  Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.

Authors:  Zhikang Ye; Ying Wang; Luis Enrique Colunga-Lozano; Manya Prasad; Wimonchat Tangamornsuksan; Bram Rochwerg; Liang Yao; Shahrzad Motaghi; Rachel J Couban; Maryam Ghadimi; Malgorzata M Bala; Huda Gomaa; Fang Fang; Yingqi Xiao; Gordon H Guyatt
Journal:  CMAJ       Date:  2020-05-14       Impact factor: 8.262

Review 7.  Corticosteroids for pneumonia.

Authors:  Anat Stern; Keren Skalsky; Tomer Avni; Elena Carrara; Leonard Leibovici; Mical Paul
Journal:  Cochrane Database Syst Rev       Date:  2017-12-13

8.  Adjunct corticosteroids in children hospitalized with community-acquired pneumonia.

Authors:  Anna K Weiss; Matthew Hall; Grace E Lee; Matthew P Kronman; Seth Sheffler-Collins; Samir S Shah
Journal:  Pediatrics       Date:  2011-01-10       Impact factor: 7.124

9.  Is prolonged low-dose glucocorticoid treatment beneficial in community-acquired pneumonia?

Authors:  Marco Confalonieri; Djillali Annane; Caterina Antonaglia; Mario Santagiuliana; Ediva M Borriello; G Umberto Meduri
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

10.  Adjunctive therapies in severe sepsis and septic shock: current place of steroids.

Authors:  Didier Keh; Steffen Weber-Carstens; Olaf Ahlers
Journal:  Curr Infect Dis Rep       Date:  2008-09       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.